Vera Therapeutics, Inc.
VERANasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$315.5M | −$167.2M | −$102.0M | −$90.9M | −$34.4M | −$52.2M |
| Net income | −$299.6M | −$152.1M | −$96.0M | −$89.1M | −$32.6M | −$53.4M |
| Total assets | $734.7M | $655.7M | $175.5M | $131.4M | $83.7M | $54.6M |
| Total liabilities | $130.2M | $78.5M | $73.9M | $54.5M | $14.2M | $4.3M |
| Equity | $604.5M | $577.2M | $101.7M | $76.9M | $69.6M | −$89.3M |
| EPS (diluted) | $-4.66 | $-2.75 | $-2.25 | $-3.35 | $-2.43 | — |
| Shares out. | 64.2M | 55.3M | 42.7M | 26.6M | 13.4M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −49.6%
- Return on assets
- −40.8%
- Return on capital (ROCE)
- −46.3%
- Liabilities / assets
- 17.7%
- Debt / equity
- 0.22×
- Book value / share
- $9.41
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 4.64safe
- Accruals / assets
- −8.0%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2025-05-15Atacicept in Subjects With IgA Nephropathy
- Phase 2Active Not Recruitingreadout ~2026-09Monthly Dosing of Atacicept in IgAN
- Phase 2Recruitingreadout ~2027-11Atacicept in Multiple Glomerular Diseases
- Phase 2Enrolling By Invitationreadout ~2028-05-31A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Price T Rowe Associates Inc /Md/Passive (13G)May 15, 2026
- Point72 Asset Management, L.P.Passive (13G)Apr 1, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Deep Track Capital, LpPassive (13G)Mar 11, 2026
- Sofinnova Venture Partners X, L.P.Activist (13D)Mar 5, 2026
- Fmr LlcPassive (13G)Feb 5, 2026
- Kynam Capital Management, LpPassive (13G)Aug 14, 2025
- Flynn James EPassive (13G)Jun 11, 2025
- Avoro Capital Advisors LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Fordyce MarshallOfficer — PRESIDENT AND CEO | May 12, 2026 | Sell | 14,219 | $36.64 |
| Fordyce MarshallOfficer — PRESIDENT AND CEO | Apr 14, 2026 | Sell | 14,130 | $43.66 |
| Wright-Mitchell JaneOfficer — Chief Legal Officer | Mar 23, 2026 | Grant | 42,403 | $0.00 |
| Young Joseph ROfficer — SVP, FINANCE, CHIEF ACCT OFFCR | Mar 13, 2026 | Option exercise | 10,000 | $3.94 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 10.1M | 10.0 | +7.4% |
| Apr 30, 2026 | 9.4M | 9.5 | -4.9% |
| Apr 15, 2026 | 9.9M | 6.9 | +1.1% |
| Mar 31, 2026 | 9.8M | 7.8 | +18.3% |
| Mar 13, 2026 | 8.3M | 6.2 | +8.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 26, 2026
- Results of operationsMay 7, 2026
- Director / officer changeMar 9, 2026
- Results of operationsFeb 26, 2026
- Director / officer changeDec 18, 2025
- Other material eventDec 10, 2025
- Director / officer changeNov 26, 2025
- Other material eventNov 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.